Handelsavisen
prelaunch
Companies Healthcare STLL.ST
ST
STLL.ST Nasdaq Stockholm Medical Equipment, Supplies & Distribution

Stille AB

kr257,00
Open in Charts → Attach watcher ⌖
SEK
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
12,9 %
ROE
7,9 %
Net margin
9,8 %
Debt / equity
0,15
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Stille AB is a medical equipment and supplies company that provides healthcare services and equipment, primarily generating revenue through the sale of medical devices and related services.

Business. Stille AB (STLL.ST) is a healthcare company operating within the Medical Equipment, Supplies & Distribution industry. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. As specific segment and geographic data are not provided, the company is described at the industry level as a provider of medical equipment and supplies.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target279,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
279,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
7,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning STLL.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to STLL.ST. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Stille AB (STLL.ST) is a healthcare company operating within the Medical Equipment, Supplies & Distribution industry. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. As specific segment and geographic data are not provided, the company is described at the industry level as a provider of medical equipment and supplies.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    Stille AB maintains a conservative capital structure with a debt-to-equity ratio of 0.15, indicating a low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 3.52, suggesting strong short-term liquidity. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints.

    In terms of profitability, Stille AB's return on equity (ROE) of 7.86% and return on assets (ROA) of 5.28% are below the industry median for medical equipment and supplies companies, indicating that the company is underperforming relative to its peers in generating returns from equity and assets. The operating margin, calculated as operating income of 73.24 million SEK on revenue of 567.63 million SEK, is 12.91%, which is in line with the industry average.

    Geographically, Stille AB's revenue is concentrated in its domestic market, with no disclosed international segments. This concentration increases exposure to local economic and regulatory risks. The company's revenue concentration in a single geographic region is a notable risk factor, as it limits diversification and exposes the company to regional economic downturns.

    Looking ahead, Stille AB is projected to experience modest revenue growth, with a free cash flow of 68.47 million SEK and capital expenditures of -20.59 million SEK. The company's operating cash flow of 36.06 million SEK supports its liquidity position, but the negative capital expenditures suggest a potential reduction in investment in long-term assets. The company's growth trajectory is expected to remain stable, with no significant changes in revenue or operating performance anticipated in the near term.

    The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to its negative net cash position after accounting for total debt, which could limit its ability to meet short-term obligations. The dilution risk is low, as the company has not issued additional shares recently, and there is no indication of a dilutive event in the near future. The company's capital structure remains stable, with no significant changes in shares outstanding or dilution potential.

    Recent events and disclosures indicate that Stille AB has not issued any new shares or engaged in significant capital-raising activities. The company's financial statements show a consistent pattern of revenue and profit generation, with no material changes in its business operations or strategic direction. Analysts have provided a mean price target of 279.00 SEK, with a single "buy" recommendation and no "strong buy" or "hold" ratings, suggesting a cautious outlook from the investment community.

    Key takeaways
    • Stille AB has a conservative capital structure with a low debt-to-equity ratio of 0.15.
    • The company's return on equity (7.86%) and return on assets (5.28%) are below the industry median, indicating underperformance in generating returns.
    • Revenue is concentrated in a single geographic region, increasing exposure to local economic and regulatory risks.
    • The company is projected to maintain stable growth with a free cash flow of 68.47 million SEK and negative capital expenditures.
    • Liquidity risk is medium due to a negative net cash position after subtracting total debt.
    • Analysts have provided a mean price target of 279.00 SEK, with a single "buy" recommendation.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    kr257,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    kr708.7M
    Net cash
    -kr109.2M
    Current ratio
    3.5
    Debt / equity
    0.1
    ROA
    5.3%
    ROE
    7.9%
    Cash conversion
    65.0%
    CapEx / revenue
    -3.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    10,49
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-24 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate10,49
    Revenueno estimateno estimate709,5M SEK
    Operating incomeno estimateno estimate122,5M SEK
    Full-year consensus mean (period as reported by source) · consensus in SEK. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price targetkr279,00 · Median kr279,00
    Low kr279,00High kr279,00
    Operating income · consensus122,5M SEK
    EPS surprise
    −40,9 %
    reported vs consensus · miss
    Revenue surprise
    −20,0 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Lowkr279,00
    Meankr279,00
    Mediankr279,00
    Highkr279,00
    Spotkr257,00
    +8.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin12,9 %Above median
    Net Margin9,8 %Above median
    ROE7,9 %Above P75
    Capex / Rev-3,6 %Above median
    D/E0,15Above median
    Cash Conv0,65Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Stille AB Market data — financials · 2026-05-29
    • Stille AB Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    STLL.STCanonical
    Nasdaq Stockholm · SEK

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage